Biotechnology company developing oral integrin therapies for autoimmune and inflammatory diseases.
Morphic Holding, Inc., a pioneering biopharmaceutical firm, specializes in the exploration and advancement of oral small-molecule integrin therapies designed to tackle a broad spectrum of ailments including autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer. Leading its portfolio are MORF-057, an a4ß7-specific integrin inhibitor currently undergoing Phase 1 clinical trials for treating inflammatory bowel disease, alongside preclinical trials aimed at addressing idiopathic pulmonary fibrosis and other fibrotic diseases.
The company is actively developing avß6 for the treatment of fibrotic diseases and avß8 for combating solid tumors, underscoring its commitment to advancing therapeutic options across diverse medical fields. Morphic Holding, Inc. engages in strategic collaborations to bolster its research initiatives, including a pivotal research collaboration with Engitix Ltd to identify potential targets for Morphic's integrin technology in fibrostenotic inflammatory bowel disease (IBD). Additionally, partnerships with Schrödinger, LLC and Children's Medical Center Corporation underscore its dedication to innovation and expansion in therapeutic and diagnostic applications.
Morphic Holding, Inc. operates with global ambitions, fortified by its extensive collaboration agreements with industry leaders such as AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc., focused on the discovery and development of integrin-based therapeutics. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic Holding, Inc. continues to pioneer advancements in integrin-targeted therapies, aiming to transform the landscape of medical treatments worldwide.